Nombre del producto:3-[6-(hydroxymethyl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione

IUPAC Name:3-[6-(hydroxymethyl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione

CAS:2803882-16-6
Fórmula molecular:C14H14N2O4
Pureza:95%+
Número de catálogo:CM1044949
Peso molecular:274.28

Unidad de embalaje Stock disponible Precio($) Cantidad
CM1044949-50mg in stock ƐƐǫǑ
CM1044949-100mg in stock ƐŪŞȅ
CM1044949-500mg in stock ȅƴǑŞ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :2803882-16-6
Fórmula molecular:C14H14N2O4
Punto de fusión:-
Código de sonrisas:OCC1=CC=C2CN(C3CCC(=O)NC3=O)C(=O)C2=C1
Densidad:
Número de catálogo:CM1044949
Peso molecular:274.28
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Column Infos

MRT-2359
Aberrant MYC pathway activation is found in cancer cells, while MYC-induced protein translation depends on GSPT1. Molecular glues targeting GSPT1 is identified as a potential treatment method in oncology. Monte Rosa’s MRT-2359 is an oral and selective molecular glue degrader of the translation termination factor GSPT1. The targeted GSPT1 degradation results in disrupting MYC-driven protein translation and reducing MYC-oncogenic signaling.
MRT-2359 is in an ongoing phase 1/2 study in MYC-driven solid tumors with a current assessment of 0.75 mg dose level. The final phase 2 dose determination and updated clinical results are anticipated in the second half of 2024. MRT-2359 previously received Fast Track Designation in patients with previously treated, metastatic NSCLC with L-MYC or N-MYC expression, Orphan Drug Designation in small cell lung cancer (SCLC), and Fast Track Designation in previously treated, metastatic SCLC with L-MYC or N-MYC expression.

Related Products